A phase II study of active specific immunotherapy and5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma

[1]  Mark M. Davis,et al.  Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  H. Lyerly,et al.  Assays for monitoring cellular immune responses to active immunotherapy of cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  G. Giaccone,et al.  Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Lokich,et al.  5‐Fluorouracil–induced small bowel toxicity in patients with colorectal carcinoma , 2000, Cancer.

[5]  S. Steinberg,et al.  Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. , 1999, Journal of immunology.

[6]  M. Hanna,et al.  Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial , 1999, The Lancet.

[7]  P. Srivastava,et al.  Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. , 1997, Science.

[8]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[9]  J. P. Pignon,et al.  Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.

[10]  C. Tangen,et al.  Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report , 1995, Annals of Internal Medicine.

[11]  Marco Lorenzi,et al.  Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. , 1994, Gastroenterology.

[12]  H. Rockette,et al.  The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Norbertus C. Robben,et al.  The syndrome of 5‐fluorouracil cardiotoxicity. An elusive cardiopathy , 1993, Cancer.

[14]  M. Hanna,et al.  Immunotherapy of metastases enhances subsequent chemotherapy. , 1982, Science.

[15]  M. Hanna,et al.  Active specific immunotherapy of residual micrometastasis , 1979, Cancer Immunology, Immunotherapy.

[16]  M. Hanna,et al.  Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. , 1979, Cancer research.

[17]  J. Sokal.  Measurement of Delayed Skin-Test Responses , 1975 .

[18]  J.E.H. Pendower.  Cancer of the colon , 1973 .

[19]  J. Madden,et al.  CANCER OF THE COLON. , 1964, American journal of surgery.

[20]  J. Manola,et al.  Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Wieand,et al.  Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  V. Torri.  Fluorouracil and folinic acid in colon cancer , 1996 .

[23]  J. Lokich,et al.  The syndrome of 5‐fluorouracil cardiotoxicity: An elusive cardiopathy , 1993, Cancer.